Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
1. An antigen binding molecule (ABM) that specifically binds to human EGFR, the ABM comprising:
a heavy chain variable domain comprising:
(a) a heavy chain complementarity determining region 1 (CDR1) comprising: SEQ ID NO:53 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 31, 32, 33, 34, 35, and a combination thereof; SEQ ID NO:59 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 27, 28, 30, 31, 32, and a combination thereof; or SEQ ID NO:65 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 27, 28, 30, 31, 32, 33, 34, 35, and a combination thereof,
(b) a heavy chain CDR2 comprising SEQ ID NO:75 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 52a, 53, 54, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, and a combination thereof,
(c) a heavy chain CDR3 comprising SEQ ID NO:107 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof, and
a light chain variable domain comprising:
(a) a light chain CDR1 comprising SEQ ID NO:113 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 24, 25, 26, 27, 29, 30, 31, 32, 33, and a combination thereof,
(b) a light chain CDR2 comprising SEQ ID NO:115 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 51, 52, 53, 54, 55, 56, and a combination thereof,
(c) a light chain CDR3 comprising SEQ ID NO:117 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 89, 90, 91, 92, 93, 94, 95, 96, 97, and a combination thereof,
wherein the heavy chain variable domain comprises phenylalanine at amino acid residue 29, asparagine at amino acid residue 52, tyrosine at amino acid residue 56, and valine at amino acid residue 100b,
wherein the light chain variable domain comprises asparagine at amino acid residues 34 and 50,
wherein the amino acid residue number is according to Kabat numbering, and
wherein the ABM does not comprise a light chain variable domain selected from the group consisting of: SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, and SEQ ID NO:147.
2. An ABM that specifically binds to human EGFR, the ABM comprising:
(a) a heavy chain variable domain comprising a sequence derived from SEQ NO:15 having a conservative amino acid substitution in a CDR at an amino acid residue selected from the group consisting of:
(1) 31, 32, 33, 34, 35, 52a, 53, 54, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof of a Kabat heavy chain CDR;
(2) 27, 28, 30, 31, 32, 52a, 53, 54, 55, 57, 58, 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof of a Chothia heavy chain CDR; and
(3) 27, 28, 30, 31, 32, 33, 34, 35, 52a, 53, 54, 55, 57, 58, 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof of an AbM heavy chain CDR, and
(b) a light chain variable domain comprising SEQ ID NO:45 or a sequence derived therefrom having a conservative amino acid substitution in a Kabat light chain CDR at an amino acid residue selected from the group consisting of: 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 51, 52, 53, 54, 55, 56, 89, 90, 91, 92, 93, 94, 95, 96, 97, and a combination thereof,
wherein the heavy chain variable domain comprises phenylalanine at amino acid residue 29, asparagine at amino acid residue 52, tyrosine at amino acid residue 56, and valine at amino acid residue 100b,
wherein the light chain variable domain comprises asparagine at amino acid residues 34 and 50, and
wherein the amino acid residue number is according to Kabat numbering.
3. An ABM that specifically binds to human EGFR, the ABM comprising:
(a) a heavy chain variable domain comprising SEQ ID NO:15 or a sequence derived therefrom having a conservative amino acid substitution in a CDR at an amino acid residue selected from the group consisting of:
(1) 31, 32, 33, 34, 35, 52a, 53, 54, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof of a Kabat heavy chain CDR;
(2) 27, 28, 30, 31, 32, 52a, 53, 54, 55, 57, 58, 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof of a Chothia heavy chain CDR;
(3) 27, 28, 30, 31, 32, 33, 34, 35, 52a, 53, 54, 55, 57, 58, 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof of an AbM heavy chain CDR, and
(b) a light chain variable domain comprising a sequence derived from SEQ ID NO:45 having a conservative amino acid substitution in a Kabat light chain CDR at an amino acid residue selected from the group consisting of: 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 51, 52, 53, 54, 55, 56, 89, 90, 91, 92, 93, 94, 95, 96, 97, and a combination thereof,
wherein the heavy chain variable domain comprises phenylalanine at amino acid residue 29, asparagine at amino acid residue 52, tyrosine at amino acid residue 56, and valine at amino acid residue 100b,
wherein the light chain variable domain comprises asparagine at amino acid residues 34 and 50,
wherein the amino acid residue number is according to Kabat numbering, and
wherein said ABM does not comprise a light chain variable domain selected from the group consisting of: SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ NO:144, SEQ ID NO:145, SEQ ID NO:146, and SEQ NO:147.
4. An isolated polypeptide comprising a heavy chain variable domain comprising:
(a) a heavy chain CDR1 comprising: SEQ ID NO:53 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 31, 32, 33, 34, 35, and a combination thereof; SEQ ID NO:59 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 27, 28, 30, 31, 32, and a combination thereof; or SEQ ID NO:65 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 27, 30, 31, 33, 34, 35, and a combination thereof,
(b) a heavy chain CDR2 comprising SEQ ID NO:79 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of 52a, 53, 54, 55, 57, 58, 59, 61, 62, 63, 64, 65, and a combination thereof, and
(c) a heavy chain CDR3 comprising SEQ ID NO:107 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof,
wherein the heavy chain variable domain comprises phenylalanine at amino acid residue 29, asparagine at amino acid residue 52, tyrosine at amino acid residue 56, and valine at amino acid residue 100b,
wherein the amino acid residue number is according to Kabat numbering, and
wherein said polypeptide does not comprise a heavy chain variable domain selected from the group consisting of: SEQ ID NO:5, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:37, and SEQ ID NO:39.
5. An isolated polypeptide comprising a light chain variable domain comprising:
(a) a light chain CDR1 comprising SEQ ID NO:113 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of 24, 25, 26, 29, 30, 31, 32, 33, and a combination thereof,
(b) a light chain CDR2 comprising SEQ ID NO:115 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 51, 52, 53, 54, 55, 56, and a combination thereof, and
(c) a light chain CDR3 comprising SEQ ID NO:117 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 89, 90, 91, 92, 93, 94, 95, 96, 97, and a combination thereof,
wherein the light chain variable domain comprises asparagine at amino acid residues 34 and 50,
wherein the amino acid residue number is according to Kabat numbering, and
wherein said polypeptide does not comprise a light chain variable domain selected from the group consisting of: SEQ ID NO:45, SEQ ID NO:49, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, and SEQ ID NO:147.
6. An isolated polypeptide comprising a sequence derived from SEQ ID NO:15 having a conservative amino acid substitution in a CDR at an amino acid residue selected from the group consisting of:
(a) 31, 32, 33, 34, 35, 52a, 53, 54, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof of a Kabat heavy chain;
(b) 27, 28, 30, 31, 32, 52a, 53, 54, 55, 57, 58, 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof of a Chothia heavy chain; and
(c) 27, 28, 30, 31, 32, 33, 34, 35, 52a, 53, 54, 55, 57, 58, 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof of an AbM heavy chain CDR,
wherein the sequence derived from SEQ ID NO:15 comprises phenylalanine at amino acid residue 29, asparagine at amino acid residue 52, tyrosine at amino acid residue 56, and valine at amino acid residue 100b, and
wherein the amino acid residue number is according to Kabat numbering.
7. An isolated polypeptide comprising a sequence derived from SEQ ID NO:45 having a conservative amino acid substitution in a Kabat light chain CDR at an amino acid residue selected from the group consisting of: 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 51, 52, 53, 54, 55, 56, 89, 90, 91, 92, 93, 94, 95, 96, 97, and a combination thereof,
wherein the sequence derived from SEQ ID NO:45 comprises asparagine at amino acid residues 34 and 50,
wherein the amino acid residue number is according to Kabat numbering, and
wherein said polypeptide does not comprise a sequence selected from the group consisting of: SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:146, and SEQ ID NO:147.
8. A composition comprising the ABM of claim 1 and a pharmaceutically acceptable carrier.
9. The ABM of claim 1 , wherein the ABM is conjugated to a label.
10. The ABM of claim 9 , wherein the label is selected from the group consisting of a radiolabel, an enzyme label, and a fluorochrome label.
11. The ABM of claim 1 , wherein the ABM is conjugated to a therapeutic agent.
12. The ABM of claim 11 , wherein the therapeutic agent is selected from the group consisting of a therapeutic drug, a toxin, a lymphokine, and a tumor-inhibitory growth factor.
13. The ARM of claim 1 , wherein the ABM is conjugated to a cytotoxic moiety.
14. The ABM of claim 13 , wherein the cytotoxic moiety is selected from the group consisting of a cytotoxic drug, an enzymatically active toxin, an enzymatically active fragment of a toxin, and a radioactive isotope.
15. The ABM of claim 1 , wherein the ABM is conjugated to an enzyme capable of converting a prodrug into a cytotoxic drug.
16. A method of targeting cells expressing EGFR in a subject comprising administering to said subject the composition of claim 8 .
17. An isolated polypeptide comprising a heavy chain variable domain comprising:
(a) a heavy chain CDR1 comprising: SEQ ID NO:53 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 31, 32, 33, 34, 35, and a combination thereof; SEQ ID NO:59 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 27, 28, 30, 31, 32, and a combination thereof; or SEQ ID NO:65 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 27, 28, 30, 31, 32, 33, 34, 35, and a combination thereof,
(b) a heavy chain CDR2 comprising SEQ ID NO:79 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 52a, 53, 54, 55, 57, 58, 59, 60, 62, 63, 64, 65, and a combination thereof, and
(c) a heavy chain CDR3 comprising SEQ ID NO:107 or a sequence derived therefrom having a conservative amino acid substitution at an amino acid residue selected from the group consisting of: 95, 96, 97, 98, 99, 100, 100a, 101, 102, and a combination thereof,
wherein the heavy chain variable domain comprises phenylalanine at amino acid residue 29, asparagine at amino acid residue 52, tyrosine at amino acid residue 56, and valine at amino acid residue 100b,
wherein the amino acid residue number is according to Kabat numbering, and
wherein said polypeptide does not comprise a heavy chain variable domain selected from the group consisting of: SEQ ID NO:5, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:37, and SEQ ID NO:39.